Mirati Therapeutics
€0.000000
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
People Also Follow
This list is based on the watchlists of people on Stock Events who follow 26M.STU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Show more...
CEO
Mr. David D. Meek
Employees
413
Country
United States
ISIN
US60468T1051
Listings
0 Comments
Share your thoughts
FAQ
What is Mirati Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Mirati Therapeutics stocks are traded under the ticker 26M.STU.
How many employees does Mirati Therapeutics have?▼
As of July 08, 2026, the company has 413 employees.
In which sector is Mirati Therapeutics located?▼
Mirati Therapeutics operates in the Other sector.
When did Mirati Therapeutics complete a stock split?▼
Mirati Therapeutics has not had any recent stock splits.
Where is Mirati Therapeutics headquartered?▼
Mirati Therapeutics is headquartered in San Diego, United States.